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High-throughput sequencing technologies have become fundamental for the identification of 
disease-causing mutations in human genetic diseases both in research and clinical testing contexts. 
The cumulative number of genes linked to rare diseases is now close to 3,500 with more than 1,000 
genes identified between 2010 and 2014 thanks to the early adoption of Exome Sequencing 
technologies. However, despite these encouraging figures, the success rate of clinical exome 
diagnosis remains low due to several factors including wrong variant annotation and non-optimal 
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In this review, we describe the critical steps of variant annotation and filtration processes to 
highlight a handful of potential disease-causing mutations for downstream analysis. We report the 
key annotation elements to gather at multiple levels for each mutation, and which systems are 
designed to help in collecting this mandatory information. We describe the filtration options, their 
efficiency and limits and provide a generic filtration workflow and highlight potential pitfalls through 
a use case. 
Keywords 




The identification of human disease-causing mutations has relied for decades on Sanger sequencing 
and pre-screening technologies such as Single Strand Conformational Polymorphism (SSCP) or 
Denaturating Gradient Gel Electrophoresis (DGGE). This process was very slow and costly especially 
when genetic heterogeneity occurred. More importantly, it was difficult to apply this approach to 
large genes such as DMD (79 exons) or TTN (363 exons). With the rapidly developing high 
throughput solid phase sequencing technologies also known as Next Generation Sequencing (NGS), 
the strategy of gene hunting and diagnosis has drastically improved. In fact, in less than ten years, 
these NGS technologies have moved from gene panel sequencing (100 Mb for the Roche GS FLX 
system) to whole genome sequencing (1500 Gb for the Illumina HiSeq4000) and from research 
context only to clinical practice. The limitation is no longer the sequencing of one, many or all genes, 
but rather the sequence analysis and interpretation. Traditionally, scientists were afforded the 
luxury to develop expertise in a limited number of disease genes over a significant period of time. 
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2013) where the expectation is to understand and interpret the suite of genes and their network of 
interactions implicated in disease. This next generation sequencing revolution now relies heavily on 
the field of bioinformatics, its tools, methods and analysis strategies to gather, store, analyze and 
mine the data in order to make informed decisions. 
Despite the tens of thousands of exomes and genomes that have been studied (for instance, Exome 
Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org), we have only 
a limited understanding of the molecular mechanisms underpinning the human genome variability, 
especially in the context of rare human genetic diseases (see article from Collod-Béroud et al. in this 
issue). In fact, most disease-causing mutations are private (specific to a family) and the availability of 
functional tests to demonstrate their pathogenicity is limited. As such, distinguishing neutral 
mutations from disease-causing ones is challenging. This is even amplified for rare diseases, which 
are defined in Europe as conditions with a frequency below 1:2000 (Regulation (EC) N°141/2000 of 
the European Parliament and of the Council of 16 December 1999 on orphan medicinal products, 
http://ec.europa.eu/health/files/eudralex/vol- 1/reg_2000_141/reg_2000_141_en.pdf). It is 
estimated that more than 7,000 rare human genetic diseases exist (https://globalgenes.org/rare-
diseases-facts-statistics/), most of them being very rare. A review from Orphanet 
(http://orphadata.org/data/xml/en_product2_prev.xml) revealed that the majority consist of a 
handful of published reports describing a few individuals with a previously unidentified genetic 
syndrome, see Figure 1.  
 
Despite this apparent low number of affected individuals, it is estimated that all together the rare 
diseases account for up to 6-8% of the global population having a strong socio-economic impact 
(http://www.ema.europa.eu). To diagnose most of these rare diseases by 2020, the International 
Rare Diseases Research Consortium (IRDiRC) was launched in April 2011. It supports international 
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(Turner et al. 2015). At the time of writing this manuscript, the cumulative number of new genes 
linked to rare diseases was 3,350 with 1,000 identified between 2010 and 2014, while 350 new rare 
diseases were described during this period (http://irdirc.org). Most of these genes have been 
identified as a result of both the revolution of NGS and advanced bioinformatics techniques. 
In contrast, this success is tempered by clinical exome diagnosis which has a success rate of only 26% 
(Yang et al. 2013). This relatively low success rate may be due to a number of factors, namely: a) 
technical limitations such as the absence of the disease-causing mutation in the captured DNA; b) a 
poor capture of some exonic regions (GC-reach regions); c) a low sequencing depth; c) a poor 
sequencing quality of read extremities; d) a mutation type not compatible with NGS technologies 
such as triplet expansion or large structural genomic variation (Gilissen et al. 2012); e) limitation of 
the bioinformatics data analysis pipeline; f) presence of pseudogenes or repeated regions, which 
may lead to inadequate mapping and wrong calling of mutations (false positives); g) limitation of the 
mapping process as no "gold standard" exist and a compromise has to be made between speed and 
accuracy, or h) wrong annotation in databases which may lead to misinterpretation of a disease-
causing mutation. 
The objective of this paper is to review the critical steps of variant annotations and filtration in order 
to guide users to collect the most appropriate elements related to each mutation and apply the 
proper filtration options to rapidly select a handful of candidate disease-causing mutations for 
downstream validation.  
 
2. Variants annotation 
The variant annotation process places mutations identified by the variant calling step (see Beltran et 
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variants of interest based upon a combined filtration of the collected data from one or multiple 
samples. 
The main objective of this process is to gather substantial information at the variant and the gene 
levels. This will include the variants’ data quality, their localization at the genomic, gene and 
transcripts levels, their genotype, their frequency in the general population, their impact at the 
mRNA and protein levels, the conservation among species of the affected protein residues, the 
variant pathogenicity prediction and reported associations with diseases. At the gene level, they 
include the gene function, its spatiotemporal expression pattern, its involvement in various 
pathways and its involvement in various phenotypes/diseases. 
 
2.1 Annotations at the variant level 
Currently, several methods are available for variant quality assessment depending on the variant 
calling tool such as UnifiedGenotyper GATK and HaplotypeCaller GATK (McKenna et al. 2010), 
SamTools (Li et al. 2009) or Platypus (Rimmer et al. 2014). These bioinformatics tools provide two 
scores: i) the variant quality score or the probability that this variation is real. It is provided as a 
Phred quality score (Q score) (Ewing and Green 1998) to assess the probability that a given base is 
called incorrectly; and ii) the genotype quality score, which is also a Phred quality score  to assess 
the probability that the given genotype is incorrect. 
The description of the localization of the mutation includes various stages. The first stage is the 
genomic coordinates of the variation and is dependent of the version of Human Genome assembly, 
currently GRCh37 or GRCh38. The second stage is the localization at the gene and transcripts level. It 
is dependent of the selected annotation of the human reference genome. It is provided by Ensembl, 
the University of California Santa Cruz (UCSC), or the National Center for Biotechnology Information 
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only 53% of junction reads mapping at the same genomic location depending of the used gene 
model (Zhao and Zhang 2015). It is thus usually recommended for protein coding genes to use the 
Consensus Coding Sequence (CCDS), which is the result of a collaborative effort to maintain a 
dataset of protein-coding regions that are identically annotated on the human and mouse reference 
genome assemblies. CCDS are consistently represented by the NCBI, Ensembl, and UCSC Genome 
Browsers (Pruitt et al. 2009). When combining data from different sources, it is highly recommended 
to use annotations performed using the same reference genome. 
Once the genomic coordinates have been determined, the HGVS nomenclature is usually used to 
name the mutations at the cDNA level for all transcripts and protein level for coding genes. Once 
again, the translation from a genomic nomenclature to a cDNA nomenclature may result in 
differences based on the variant caller and the annotation tool. This is especially true for insertions 
and deletions in a repeated sequence. It may thus be interesting to control mutations nomenclature 
after the initial annotation step using a system able to correct such errors. One such tool is the 
Variant Effect Predictor from Ensembl (VEP) (Yates et al. 2015). In an attempt to evaluate the impact 
of functional annotation using various reference systems and tools, McCarthy et al. quantified the 
extent of differences in annotation of 80 million variants from a whole-genome sequencing study. 
They compared results from the ANNOVAR and VEP software using REFSEQ and ENSEMBL 
transcripts. They reported only 44% agreement in annotations for putative loss-of-function variants 
using ANNOVAR. They also support data from Zhao et al. (Zhao and Zhang 2015) showing that the 
splicing variants were the category with the greatest discrepancy. They concluded that the 
annotation step must be considered carefully, and that a conscious choice should be made to select 
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Another key annotation element is the frequency of the variant in the general population. If ideally 
this general population should match the sample's origin, it is usually not available and data is 
captured from large scale projects such as the 1000 genome project (1000 Genomes Project 
Consortium et al. 2015), dbSNP (Sherry et al. 2001), the EVS (http://evs.gs.washington.edu/EVS/) or 
the EXAC consortium (Lek et al. 2015). It is important to recognise that these datasets are not 
mutually exclusive as there is significant overlap and should therefore not be simply combined to 
extrapolate a global frequency. In addition, these datasets are not representative of a global 
population per se as they contain "assumed to be healthy" individuals and samples from selected 
individuals with a particular condition. Note that laboratories, which routinely perform high-though 
put sequencing usually build internal frequency databases to exclude potential artefacts. 
Variant nomenclature and localization 
The annotation of the impact of the DNA mutation at the mRNA and the protein levels is complex. If 
the consequence at the protein level is easy to predict and report using the HGVS nomenclature (p.), 
it is only a prediction and should be considered as such. For example, a frameshift mutation 
predicted to result in a premature termination codon and therefore to a shorter protein, usually 
does not exist in reality because of the nonsense mediated decay phenomenon (Miller and Pearce 
2014). Another example is the prediction of a protein harboring a missense mutation that indeed 
does not exist as its primary impact is at the mRNA level as exemplified by the c.2167G>A 
(p.Asp723Asn) of the FBN1 gene that lead to the exon 17 skipping (Evangelisti et al. 2010). The 
impact of mutations at the mRNA level is even less documented as it is annotated as splicing 
mutation if localized in the donor or acceptor splice site regions, while the splicing machinery 
recognizes many signals such as exonic splicing enhancers and silencers and is considered as one of 
the most complex process of the cell (Nilsen 2003). Only few annotation tools are now including data 
from the Human Splicing Finder system that provides predictions for the impact of any mutation on 
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by AdaBoost and Random Forest from dbscSNV (Wang et al. 2010). The VEP system integrates 
various modules allowing to run external algorithms such as MaxEntScan (Yeo and Burge 2004), 
GeneSplicer (Pertea et al. 2001) or the dbNSFP (Liu et al. 2016) for splice sites effect predictions. 
Affected protein residue annotation 
The next annotation for variations is the conservation of affected protein residues. This information 
is usually restricted to single nucleotide variations that may result in missense mutations. It could be 
used as the result of selection pressure to maintain a specific amino acid at a given position because 
of its importance for the structure or the function of the protein. Typically, the higher the 
conservation, the higher the probability that a missense could impact the protein function. Most 
annotators are using conservation data extracted from the dbNSFP (Liu et al. 2016) that colligate 
data from PhyloP (Pollard et al. 2010), PhastCons (Siepel et al. 2006), GERP++ (Davydov et al. 2010) 
and Siphy (Garber et al. 2009). This gives access to conservation data from 27, 46 and 100 species, 
respectively, when using the GRCh37/38 reference genome. 
Variant pathogenicity 
Variants are also annotated for their potential pathogenicity using multiple algorithms and systems. 
Most annotator systems provide access to the following predictors: SIFT (Sim et al. 2012) Polyphen2 
(Adzhubei et al. 2010), LRT (Chun and Fay 2009), MutationTaster (Schwarz et al. 2014), Mutation 
Assessor (Reva et al. 2011), FATHMM (Shihab et al. 2013), MetaSVM and MetaLR (Dong et al. 2015), 
CADD (Kircher et al. 2014), VEST3 (Carter et al. 2013), PROVEAN (Choi et al. 2012), fitCons (Gulko et 
al. 2015), fathmm-MKL (Shihab et al. 2015), and DANN (Quang et al. 2015). Only the VarAFT 
annotator (http://varaft.eu) provides annotations from the most efficient predictor for cDNA 
substitutions: UMD-Predictor (Salgado et al. 2016). 
The final annotation at the variant level corresponds to its association with diseases. This 
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COSMIC (Forbes et al. 2015), UNIPROT (UniProt Consortium 2014) or HGMD (Stenson et al. 2003). It 
is important to keep in mind that the quality of these associations is highly variable and that some 
resources are not freely available. 
2.2 Annotations at the gene level 
As many variations are new or lacking annotation, it is useful to access data at the gene level. Global 
functional information is provided by the Gene Ontology at the cellular component, molecular 
function and biological process levels (Gene Ontology Consortium 2015). Additionally, data from 
tissue expression can be obtained from the Genotype Tissue Expression resource (GTEx) (Carithers et 
al. 2015), the Gene Expression Atlas (Petryszak et al. 2016) and organism model databases such as 
the Mouse Genome Institute (Bult et al. 2016). Unfortunately, the ability to integrated this data is 
not available for most annotators and often requires developing specific plugins such as the VEP 
annotator GXA.pm plugin to gather data from the Gene Expression Atlas.  
Another level of genes annotation is their involvement in various pathways, these data can be found 
in BioCarta (Nishimura 2001), the Pathway Interaction Database (PID) (Schaefer et al. 2009), the 
Reactome (Fabregat et al. 2016), the WikiPathways (Kutmon et al. 2016), and KEGG (Kanehisa et al. 
2016). Despite their utility for gene hunting, the information captured in these tools are not 
automatically incorporated during the annotation process. They are only available through external 
links. 
As for annotations at the variant level, it is important to capture the phenotypes associated to 
mutations from a particular gene. The Online Mendelian Inheritance in Man (OMIM) resource is 
providing such information (Amberger et al. 2014). Other resources such as ClinVar, HGMD might 
also be used as part of the annotation process. 
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Different types of annotation software are available either through command line, webservices or 
web interface. They require data in different format, most allowing direct annotation of VCF files. 
They are compatible with either a single or multiple release versions of the human reference 
genome and allow annotation of SNP, Indels and CNV for only a limited number. As discussed, no 
system is providing annotations at all levels (Table 1). To easily handle annotations at the variant and 
gene levels most of the systems rely on the dbNSFP database developed for functional prediction 
and annotation of all potential non-synonymous single-nucleotide variants in the human genome 
(Liu et al. 2016). 
3. Selection of potential disease-causing mutations  
Once annotations at the gene and variant levels have been performed, the user needs to reduce the 
significant number of variations (usually in the tens of thousands) to a small, manageable number of 
putative candidate disease-causing mutations for further experimental validation. This filtering 
process is likely the most critical process of NGS analysis. The aim is to combine filtration criteria to 
exclude spurious variants by taking into account various parameters such as: the mode of 
inheritance, the disease frequency, the pathogenicity prediction of variations, the gene expression 
pattern, known relations between the observed phenotype and gene mutations, and so forth. 
Currently, as there is no gold standard describing an optimized filtration process for all situations, 
there are two options to proceed. Option one is to employ a semi-automatic prioritization systems 
such as eXtasy (Sifrim et al. 2013), OMIM Explorer (James et al. 2016) or Exomiser (Smedley et al. 
2015). This approach is proven to be very useful in situations where the phenotype is clearly 
described (mostly available in clinical diagnostic context) using the proper ontology such as the 
Human Phenotype Ontology (HPO) (Köhler et al. 2014) or the disease name (Amberger et al. 2014), 
as well as for gene hunting for the most advanced systems such as Exomiser and Phenolyzer  (Yang 
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The alternate option is to adopt a fully manual prioritization procedure based on expert knowledge 
related to the disease phenotype and genes functions. This approach is greatly facilitated by the use 
of user friendly filtration tools such as VarAFT (http://varaft.eu), FM Filter (Akgün et al. 2016), 
VarSifter (Teer et al. 2012), ExomeSuite (Maranhao et al. 2014), wKGGSeq (Li et al. 2015) or 
customizable filtration tools that require advance knowledge in informatics as they must be used 
through command-line scripts such as ANNOVAR (Wang et al. 2010) or GEMINI (Paila et al. 2013). 
The semi-automatic prioritization systems use different prioritization algorithms and data. As 
reported by Rehm et al., the choice of the filtering process may differ across case types and requires 
a high level of expertise in genetics and molecular biology (Rehm et al. 2013). We will here describe 
the various steps that may be combined for manual prioritization. Table 2 lists some filtration 
systems and available filtration options.  
3.1 Mode of inheritance 
The initial step is linked to the mode of inheritance allowing the selection of either homozygous, 
heterozygous or compound heterozygous mutations either inherited or de novo. This selection 
process is facilitated when multiple samples from the family (trio) or the patient (somatic events) are 
available. As reported by Farwell et al., the diagnostic rate is higher among families undergoing a trio 
Whole Exome Sequencing (WES) (37%) as compared to a singleton (21%) (Farwell et al. 2015).These 
data were confirmed by Sawyer et al., reporting WES success rates of 23% for singletons, 32% for 
sibling pairs, and 34% for families (Sawyer et al. 2016). For instance, in the case of recessive 
conditions, the disease-causing mutations mainly correspond to compound heterozygous mutations 
for non-consanguineous families except for situations where a mutations is frequent in the 
population such as the ∆F508 mutation (NM_000492.3: c.1521_1523del) of the CFTR gene (Alfonso-
Sánchez et al. 2010) and to homozygous mutations for consanguineous families. The most advanced 
systems such as VarAFT allow supporting of these hypotheses in difficult missing data contexts 
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3.2 Mutation localization 
The mutation localization is usually the second parameter. Variants from key genomic regions 
(exons, splice sites) are usually selected while variants from other genomic regions (3' and 5'UTR, 
intronic regions) are discarded. In fact, if pathogenic mutations have been reported in 3' and 5' UTR, 
they mainly correspond to trinucleotide repeat expansions as illustrated by Spinocerebellar Ataxia 
type12 (#604326) and Fragile X tremor/Ataxia syndrome (#300625) for 5'UTR and Spinocerebellar 
Ataxia type 8  (#608768), Myotonic Dystrophy 1 (#160900) or Huntington disease like 2 (#606438) 
for 3' UTR (Richards et al. 2013). Nevertheless, it is important to keep in mind that these repeat 
expansions are not captured by most NGS technologies such as Illumina or Proton that generate only 
short reads. Other variants from these regions may be subsequently analyzed when no meaningful 
result is obtained.  
 
3.3 Mutation type 
It is well recognized that not all mutation types might result in an equal effect on proteins and 
diseases. Thus, it is usually considered that nonsense mutations as well as frameshift mutations have 
a strong impact while at the other end of the spectrum, synonymous changes usually have no impact 
at the protein level but may affect mRNA maturation. If in the past, synonymous changes have been 
frequently filtered-out, they are today conserved during this selection process. It is recommended to 
remove only variants belonging to the "unknown" or "in-frame deletions and insertions" mutation 
types. Other variants will be excluded through other filtration process such as pathogenicity 
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3.4 Mutation frequency 
As most genetic diseases are rare, mutation frequency could be used to exclude frequent variations 
(see paper from Collod et al. in this issue). Ideally, this information should be captured from a 
matched population. In practice it is rarely feasible and users rely on frequencies from 1000 genome 
project (1000 Genomes Project Consortium et al. 2015), dbSNP (Sherry et al. 2001), the EVS 
(http://evs.gs.washington.edu/EVS/) or the EXAC consortium (Lek et al. 2015) as mentioned in the 
annotation section. Additionally, some large scale sequencing analysis project, such as ExAC, allow at 
the same time to combine the frequency data with the level of coverage observed in order to 
provide an accurate reflection of a specific variant within a population. Depending on the mode of 
inheritance and the frequency of the disease, it is possible to calculate the theoretical threshold of 
the disease-causing mutation frequency under the assumption that all observed cases harbor a 
single mutation. For example, for an autosomal dominant disease with a frequency of 1:10000, the 
allele frequency threshold is 0.01% while for an autosomal recessive disease with the same 
frequency, the threshold is 1%.  However, obtaining this information for genetically heterogeneous 
disorders with overlapping clinical phenotypes might be challenging. 
 
3.5 Pathogenicity predictions 
During the last few years, various systems have been developed to predict the pathogenicity of 
mutation from human genes. They contain predictions for synonymous and non-synonymous 
changes, mutations potentially affecting mRNA splicing motifs as well as regulatory regions including 
miRNA binding sites, transcription Factor binding sites (Boyle et al. 2012), chromatin states (Ward 
and Kellis 2016) and non-coding regions (Kircher et al. 2014; Ritchie et al. 2014). It is essential for a 
critical interpretation of results to understand the strengths and limitations of each system. For 
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while they are less efficient for splicing auxiliary splicing sequences (Desmet et al. 2010). Similarly, 
predictions of the pathogenicity of missense mutations could be performed with a wide range of 
systems with accuracy ranging from 72% to 85% on a dataset of 17,329 variants (Salgado et al. 
2016). Some authors have proposed to integrate individual predictions into meta systems such as 
PON-P (Olatubosun et al. 2012) and Condell (González-Pérez and Lopez-Bigas 2011) but consensus is 
only achieved for a subset of mutations, which are often relatively easy to predict. Therefore, it is 
better to use a limited set of predictors for filtration rather than combining all predictions, which 
may result in many situations with discrepancies between predictors. For example the 
NM_022124.5:c.4488G>C (p.Gln1496His) mutation of the CDH23 gene has been reported as a 
pathogenic mutation (Bolz et al. 2001). Only the CADD, UMD-Predictor and Mutation Taster systems 
predicted this variant as pathogenic while the SIFT, Polyphen2, Condel, Provean and Mutation 
Assessor systems predicted it as a non-pathogenic mutation. In Figure 1 a Venn diagram is presented 
highlighting the predictions from the most frequently used predictors on a subset of randomly 
chosen 5,000 variations from the Uniprot dataset (Salgado et al. 2016). The 6 predictors reach 
consensus for only 3074 (61.5%) of variants, while if using only the 2 most efficient systems (UMD-
Predictor and CADD), consensus is achieved for 4275 (85.5%) variants. 
 
 
3.6 Functional evidences 
Numerous studies have resulted in functional annotations of genes in various species and a specific 
ontology has been developed to described these functional annotations: Gene Ontology (Gene 
Ontology Consortium 2015). In parallel, genes have been classified in various pathways (Nishimura 
2001; Fabregat et al. 2016; Kanehisa et al. 2016) in order to capture relationships and facilitate gene 
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various species using a number of different high throughput techniques such as in situ hybridization 
(Tomancak et al. 2002), micro arrays (Petryszak et al. 2016) and RNA-seq (GTEx Consortium 2013). 
Unfortunately, despite the importance of these data they are usually not available for filtration. 
 
3.7 Previous description in databases 
As mentioned in the beginning of this section, the description of mutations might be helpful for 
variant prioritization. In addition to variants' frequency, the availability of curated and previously 
annotated data is of primary importance. Such data can be found in Locus Specific DataBases (LSDB) 
such as LOVD (Fokkema et al. 2005), UMD (Béroud et al. 2005) and others 
(http://www.hgvs.org/locus-specific-mutation-databases) or Core databases such as HGMD (Stenson 
et al. 2003), ClinVar (Landrum et al. 2014), OMIM (Amberger et al. 2014), Uniprot (UniProt 
Consortium 2014) or RDRF (Bellgard et al. 2014). These annotations are of different qualities due to 
different curation modes ranging from full curation by experts to direct submission without review. 
In this context it is important to do not consider annotations as definitive answers but rather as 
evidences of causality. These data are usually not available for filtration but as additional 
annotations. 
 
3.8 Proposed Filtration Flowcharts 
Figure 3 proposes a standard filtration flowchart to identify disease-causing mutations in a context 
of a trio analysis for the recessive mode of inheritance. The samples were described by Kamphans et 
al. (Kamphans et al. 2013) and correspond to a family with one daughter (sample ID #464) affected 
by Mabry syndrome and her two healthy parents (samples ID #466 and 467). The flowchart is 
composed of 5 steps, however, the fifth step could be divided into functional evidences and previous 
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candidate variations/genes during the first step where the compound heterozygous hypothesis has 
been selected. Alternative hypothesis such as homozygous mutation in the daughter with 
heterozygous parents for the mutation as well as more complex hypothesis where one of the two 
parents has insufficient sequencing quality resulting in missing data, should also be investigated in 
parallel (see below). In the second step, only mutations localized in exons and their vicinity are 
conserved. This parameter corresponds to the most frequent situation and can be adjusted on a 
case by case basis especially for genes where mutations in UTR regions have been reported with a 
high frequency. The third step uses frequency information from the 3 most popular databases (EVS, 
1000 genomes and ExAC) even if they overlap (see above). The frequency threshold can be adjusted 
if the disease frequency is known or arbitrarily fixed to 1% in case of a recessive condition. For the 
fourth step, we selected only predictions from the UMD-Predictor and CADD systems. Based on user 
experience, the selection of predictors might vary. Note that in this use case, one of the two disease-
causing mutations from the PIGO gene is a missense variation (NM_032634, c.2869C>T, 
p.Leu957Phe) for which pathogenicity predictions are available, the second one being a frameshift 
deletion (NM_032634, c.2355dupC). It is important to note that in this case, the use of more 
predictions algorithms might have resulted in loss of this candidate gene as this mutation is 
predicted as being non-pathogenic by SIFT and Mutation Taster. The final step corresponds to the 
collection of additional evidence. Here only two candidate genes with compound heterozygous 
mutations were present: the AFF1 and the PIGO genes. After collection of evidences from OMIM, the 
PIGO gene can be selected as the only hypothesis compatible with the phenotype. 
In this use case the disease-causing mutations were efficiently captured which is only true for a 
limited number of situations as reported by the clinical exome diagnosis success rate of only 26% 
(Yang et al. 2013). For the negative cases it is important to consider the following hypothesis.  
Hypothesis 1: poor sequence quality in one sample leading to missing data. Only few filtration tools 
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Hypothesis 2: wrong genotype. For instance, considering only compound heterozygous hypothesis in 
a case of recessive inheritance without consanguinity. The homozygous hypothesis should always be 
evaluated as well as the compound heterozygous situation with one de novo mutation. The recently 
released TADA (Transmission And De novo Association test) model is a Bayesian model that 
combines data from de novo mutations, inherited variants and standing variants in the population. 
This approach revealed a significant power increase for gene discovery, as demonstrated through 
the studies of exome data of Autism Spectrum  Disorder (ASD) (He et al. 2013) and might be useful in 
other situations.  
Hypothesis 3:  involvement of a large rearrangement or Copy Number Variation (CNV). It is 
recognized that CNV are frequently involved in human genetic diseases with the archetype of 
Duchenne Muscular Dystrophy where they account for up to 60% of mutations (Bladen et al. 2015). 
These CNV might now be captured from WES data and various tools are available (Nam et al. 2016). 
It is therefore important to combine this information with SNV.  
Hypothesis 4: some variations could be missed by the WES technologies because they are localized 
outside captured regions (deep intronic, regulatory regions).  
Hypothesis 5: bioinformatics pipelines limitations. The alignment process could lead to wrong reads' 
mapping because of high homology between various genomic regions. This might end up with wrong 
variant calling resulting in false positives or false negatives. In addition, repeated sequences can not 
be aligned and prevent mutation identification as it is the case for trinucleotide repeats, which are 
responsible for many human diseases (Keogh and Chinnery 2013).   
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High throughput sequencing technologies that include Whole Exome Sequencing generate a high 
number of sequence variations in all individuals. Identifying disease-causing mutations among this 
large amount of data is a significant challenge. In this paper, we described the annotation and 
filtration steps that are mandatory to rapidly end up with a handful of disease-causing candidate 
mutations for further analysis. Even if the success rate is still limited, these technologies have a 
strong potential to diagnose most human monogenic diseases. To do so, it is first critical to 
understand the advantages as well as the limits of the annotation and filtration systems as incorrect 
or incomplete annotations can cause scientists both to overlook potentially disease-relevant DNA 
mutations as well as potentially dilute interesting mutations into a pool of false positives. 
Additionally, the filtration process requires experts in order to efficiently define hypothesis and 
successfully apply filtration tools. Finally, a close collaboration with clinicians is also a pre-requisite 
to avoid misclassification of patients that often prevent the disease-causing mutation discovery as 
experienced by many research teams. 
Despite the availability of many bioinformatics systems for annotation and filtration, there is no gold 
standard available to solve every situation. Some semi-automatic prioritization systems taking into 
account genotypes and phenotypes are now available and could be of interest for specific situations 
(Sifrim et al. 2013; Smedley et al. 2015; James et al. 2016). However, most users typically use a 
combination of annotation and filtration systems. This can be done manually through dedicated 
systems (Teer et al. 2012; Maranhao et al. 2014; Li et al. 2015; Akgün et al. 2016) or using 
frameworks such as the Galaxy (Goecks et al. 2010) and Yabi (Hunter et al. 2012). The latter is 
flexible enough to allow any combination of software tools and data into sophisticated analysis 
procedures. In addition, the generated workflows can be easily shared and adjusted. Despite these 
strong benefits, these systems require not only bioinformatics skills but also a full understanding of 
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With the future switch to whole genome sequencing, additional challenges will emerge such as the 
handling of very large datasets and the interpretation of new mutation types: i) deep intronic 
mutations; ii) regulatory region mutations; iii) mutations found in non-coding genes (lncRNA 
(Wapinski and Chang 2011), T-UCR, circular ncRNA, small nucleolar RNA and miRNA (Esteller 2011) 
and iv) mutations reported in extra-genic regions (Dickel et al. 2013). As reported by Berg et al., a 
significant obstacle to implementing WGS is the huge amount of information that will be generated 
even if they consider that only a small subset might be relevant for interpretation due to a lack of 
knowledge (Berg et al. 2011). Nevertheless, it is anticipated that with the global adoption of WGS, 
more data will be generated and will contribute to the development of new bioinformatics tools and 
systems to facilitate their interpretation. If people often consider sequencing costs as the major 
barrier for WGS adoption, it is important to not only consider these costs but also human resources 
required for data interpretation. In fact, human resource needs for full clinical interpretation of WGS 
data remain considerable as described by Dewey et al. who reported that approximately 100 
variants should be manually evaluated in each patient and that candidate disease causing mutation 
curation required at least one hour per variant (Dewey et al. 2014). 
It is reasonable to believe that during this WGS progressive adoption phase, most users will first 
benefit from better exonic regions coverage when compared to WES (Belkadi et al. 2015). In this 
situation they might directly benefit from all annotation and filtration systems developed for WES 
data analysis and described here before the availability of innovative annotation and filtration 
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Figure 1: Distribution of rare diseases according to their estimated prevalence. Data were 
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Figure 2: Venn diagram of pathogenicity predictions of 5,000 variants from Uniprot using CADD 
(Kircher et al. 2014), SIFT (Sim et al. 2012), Polyphen 2 (PPH2) (Adzhubei et al. 2010), Provean, 
Mutation Taster (MutTaster) (Schwarz et al. 2014) and UMD-Predictor (UMD-Pred) (Salgado et al. 
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Figure 3: Filtration flowchart for a recessive disease from a trio (father, mother and affected 
daughter) (Kamphans et al. 2013). 1st step = mode of inheritance. Only genes with compound 
heterozygous mutations found in the daughter and transmitted by the two parents are selected; 2nd 
step = mutation localization. Only mutations present in the exons and intronic regions +/-8 
nucleotides from the exon are conserved; 3rd step = frequency. Mutations with a reported frequency 
in ESP, 1000 genomes or ExAC above 1% are removed; 4th = predictions. Only mutations predicted as 
pathogenic or probably pathogenic by UMD-Predictor and CADD are conserved; 5th = other 
evidences. Genes of interest are analyzed using data from OMIM to select genes with a compatible 
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Yes Yes Yes Yes Yes Yes Yes Yes 
Genotype Yes Yes Yes Yes Yes  - Yes Yes 
Population 
frequency 
Yes  - Yes Yes Yes Yes Yes Yes 
Impact at the 
RNA level 
Yes Yes Yes  -  -  -  -  - 
Impact at the 
protein level 
Yes Yes Yes Yes Yes Yes Yes  Yes 
Conservatio
n 
Yes Yes Yes Yes  - Yes Yes Yes 
Reported 
impact 













 -  -  -  -  - Yes Yes  - 
Pathways  -  -  - Yes  -  - Yes Yes 
Tissue 
expression 
 -  -  -  -  -  -  -  - 
 
Table 2: Non-exhaustive list of filtration systems for WES. VCF = Variant Call Format; TSV = Tab-
separated values; ped file = pedigree file format; * = select variants based on the mutation genotype 
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